Company: ACBM
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001640334-25-001999
Chunk: 4

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 4
---
        Advances from related parties  174,772   26,502 Net cash provided by financing activities  174,772   26,502          Net change in cash  3,847   325 Cash at beginning of period  476   376 Cash at end of period $4,323  $701          SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for income taxes $-  $- Cash paid for interest $-  $- 

The accompanying notes are an integral part of these unaudited financial statements.

 7Table of Contents

ACRO BIOMEDICAL CO., LTD.

Notes to Financial Statements

(Unaudited)

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd. The Company’s business is the sale of cordyceps related products. Cordyceps is a fungus that is used in traditional Chinese medicine.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited Interim Financial Statements The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2024 have been omitted; and these unaudited interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the year ended December 31, 2024 included within the Company’s annual report on Form 10-K for the year ended December 31, 2024. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements